Tuesday, July 18, 2017

Home / Unlabelled / ORPHAN DRUG APPROVAL : Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) had proven to be beneficial to the prescription of rare diseases

ORPHAN DRUG APPROVAL : Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) had proven to be beneficial to the prescription of rare diseases

by Unknown on July 18, 2017

The Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) of June 2017 gave fair to these orphan drugs to be output for the following diseases.

1. The spinal cord lesion (oxymetazoline hydrochloride)

2. Amyotrophic lateral sclerosis (monoclonal antibody)

3. Congenital pachyonychia (sirolimus)

4. Gastrointestinal stromal tumors (chemical drug)

5. B cell diffuse large cell lymphoma (cell therapy)

6. Primary hyperoxaluria (enzyme)

7. Hepatocellular carcinoma (chemical drug, tirapazamine)

8. Anti-MAG neuropathy (chemical drug)

9. Retinopathy of prematurity (retinol)

Oxervate (cenegermine) in the treatment of neurotrophic keratitis has been approved to be launched in the market by the Committee for Orphan Medicinal Products (COMP).

http://ansm.fr